Objectives: To determine antibiotic susceptibility in isolates of Streptococcus pneumoniae and Haemophilus influenzae collected in 2014-16 from Russia.
Introduction
Community-acquired pneumonia (CAP) is a challenge in primary care medicine, with Streptococcus pneumoniae and Haemophilus influenzae important bacterial pathogens associated with this disease. 1, 2 Prescription decisions are made empirically, so antibiotic resistance surveillance plays a major role in the reporting and management of CAP. 3 One such study is the ongoing Survey of Antibiotic Resistance (SOAR), which is an antimicrobial resistance surveillance study of key respiratory pathogens, conducted in the Middle East, Africa, Latin America, Asia-Pacific and Commonwealth of Independent States countries since 2002. Data recently published from this study have shown large differences in antibiotic resistance in these pathogens between countries, with low resistance reported in Ukraine and high resistance in China, for example. 4, 5 High variability in resistance can often occur between countries within the same region of the world, such as Asia, 6 Africa 7 and the Gulf states. 8 Thus regular dissemination of geographically focused surveillance data is vital to guide optimum therapies for CAP. In this paper we report SOAR data for major respiratory tract pathogens collected from hospitals in Russia.
Materials and methods

Collaborating centres
The following three centres took part in the study: Federal State Autonomous Institution 'National Scientific and Practical Center of Children's Health' of the Ministry of Health of the Russian Federation, Moscow, Russia; Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia; and Scientific Research Institute of Children's Infections, St Petersburg, Russia.
Isolates of H. influenzae and S. pneumoniae were sent to a central laboratory (International Health Management Associates, Inc., Switzerland) where they were sub-cultured and re-identified. H. influenzae were reidentified by MALDI-TOF MS methodology and S. pneumoniae identity was confirmed by optochin susceptibility and bile solubility. b-Lactamase production was determined for each H. influenzae isolate by a chromogenic cephalosporin (nitrocefin) disc method. Duplicate isolates from the same patients were excluded from the analysis.
Susceptibility testing
Isolates were evaluated for antibiotic susceptibility using broth microdilution methodology recommended by CLSI. 9 Both pathogens were assessed for susceptibility to amoxicillin, amoxicillin/clavulanic acid (2:1), azithromycin, cefaclor, ceftriaxone, cefuroxime, clarithromycin, erythromycin, levofloxacin, moxifloxacin and trimethoprim/ sulfamethoxazole (1:19). S. pneumoniae was also tested for susceptibility to penicillin while H. influenzae was additionally tested for susceptibility to ampicillin.
Susceptibility to the study drugs was calculated based on CLSI breakpoints, EUCAST breakpoints and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. [10] [11] [12] These breakpoints are shown in Table 1 .
Quality control and data analysis
Quality control strains S. pneumoniae ATCC 49619, Escherichia coli ATCC 25922, H. influenzae ATCC 49247, H. influenzae ATCC 49766 and E. coli ATCC 32518 were included on each day of testing. Results of susceptibility testing were accepted if the results of the control strains were within published limits. Differences in susceptibility between age groups, source of infection and penicillin susceptibility (S. pneumoniae only) were assessed for statistical significance (where n 20) with Fisher's exact test using XLSTAT version 2011.1.05. A P value ,0.05 was considered statistically significant.
Results
S. pneumoniae
A total of 279 S. pneumoniae isolates were collected from three different centres in Russia from 2014-16. Most pneumococci came from sputum (n " 107; 38.4%) and sinuses (n " 102; 36.6%). Less frequently, isolates were from bronchoalveolar lavage (n " 36; 12.9%), middle ear effusion (n " 23; 8.2%), endotracheal aspirate (n " 7; 2.5%) and blood (n " 3; 1.1%). One isolate was from an undisclosed respiratory source. Most isolates (n " 232; 83.2%) came from children (aged 12 years), 42 (15.1%) were from adult Amoxicillin/clavulanic acid was tested at a 2:1 amoxicillin to clavulanic acid ratio; breakpoints are expressed as the amoxicillin component. PK/PD breakpoints based on high dose (4 g of amoxicillin with 250 mg of clavulanate per day for adults) shown in parentheses, 12 which is the same as CLSI for H. influenzae and one dilution higher for S. pneumoniae. patients (13-64 years) and 3 (1.1%) were from elderly patients (aged 65 years). Two isolates were from patients of unknown age.
Summary MIC and susceptibility data for all 279 S. pneumoniae isolates are shown in Table 2 . MIC distribution data are given in Table 3 .
Overall, 93.2% (260/279) of S. pneumoniae were penicillin susceptible, 4.7% (13/279) were penicillin intermediate and 2.2% (6/279) were penicillin resistant by CLSI penicillin intravenous (iv) (non-meningitis) breakpoints. However, based on CLSI penicillin oral breakpoints or EUCAST breakpoints only 67.0% (187/279) were penicillin susceptible.
S. pneumoniae isolates were 100% susceptible to levofloxacin and moxifloxacin by all three breakpoints. Amoxicillin and amoxicillin/clavulanic acid susceptibility was 92.8%-97.1% by CLSI or PK/PD breakpoints (no EUCAST breakpoints are available). Ceftriaxone was similarly effective, with 94.6% (264/279) of isolates susceptible by CLSI and PK/PD breakpoints, but less active (84.2%) by EUCAST criteria due to the lower EUCAST breakpoint. Cefuroxime was slightly less active, with 85% (237/279) of isolates susceptible by CLSI and PK/PD breakpoints and 78.5% (219/279) by EUCAST breakpoints. Cefaclor, on the other hand, had some activity by CLSI standards (76.7% susceptible; 214/279) but was poorly active (21.5% susceptible; 60/279) by PK/PD breakpoints and only 0.4% of isolates were susceptible (1/279) by EUCAST breakpoints.
Susceptibility to clarithromycin and erythromycin was seen in 68.8% (192/279) of isolates by CLSI, EUCAST and PK/PD breakpoints. Susceptibility to azithromycin was also 68.8% by CLSI breakpoints but there were slightly lower susceptibility rates, of 68.5% (191/279) and 54.5% (152/279), using EUCAST and PK/PD breakpoints, respectively. Susceptibility to trimethoprim/sulfamethoxazole was similar to that seen with macrolides and oral penicillin: 67.7% (189/279) by CLSI or PK/PD breakpoints and 68.1% (190/279) by EUCAST breakpoints.
Antibiotic susceptibility in S. pneumoniae was also compared according to specimen source, age group and penicillin susceptibility using CLSI breakpoints. There was no significant difference in antibiotic susceptibility based on patient age (data not shown). When comparing specimen sources, significant differences were only found between isolates from sinus (n " 102) and sputum (n " 107) for oral penicillin (55.9% and 75.7% susceptible, respectively, P " 0.003) and cefaclor (68.6% and 83.2%, respectively, P " 0.015), and between isolates from sinus (n " 102) and bronchoalveolar lavage (n " 36) for penicillin (55.9% and 75.0%, respectively, P " 0.049). Susceptibility to the test antimicrobials for isolates stratified by penicillin susceptibility (CLSI oral breakpoints only) is shown in Figure 1 . As stated above, all isolates were susceptible to levofloxacin and moxifloxacin, so penicillin susceptibility clearly had no effect on the activity of these antibacterials. All penicillin-susceptible isolates were susceptible to 90% of the other antibacterials tested. Amoxicillin, amoxicillin/clavulanic acid or ceftriaxone retained full activity against penicillin-intermediate isolates, but all other antibacterials studied, except fluoroquinolones, showed significantly less activity against penicillin-intermediate isolates compared with penicillin-susceptible isolates (P , 0.0001). Furthermore, all antibacterials tested, except fluoroquinolones, were significantly less active against penicillin-resistant isolates compared with penicillin-intermediate isolates (P value ranged from 0.0005 to ,0.0001). 
H. influenzae
A total of 279 H. influenzae isolates were collected from three different centres in Russia from 2014 to 2016. Infection origins of the isolates included sputum (n " 142; 50.9%), followed by sinuses (n " 97; 34.8%), bronchoalveolar lavage (n " 14; 5.0%), endotracheal aspirate (n " 7; 2.5%), middle ear effusion (n " 6; 2.2%) and Percentage susceptibility rates (with 95% CI) for antimicrobials against S. pneumoniae according to penicillin susceptibility (CLSI oral breakpoints): PSSP, penicillin-susceptible S. pneumoniae; PISP, penicillin-intermediate S. pneumoniae; PRSP, penicillin-resistant S. pneumoniae. *Susceptibility to amoxicillin, amoxicillin/clavulanic acid or ceftriaxone was significantly lower in PRSP than in PISP or in PSSP (P , 0.0001). **Susceptibility to cefuroxime or cefaclor was significantly lower in PISP or in PRSP compared with PSSP and in PRSP compared with PISP (all P , 0.0001). ***Susceptibility to the macrolides and trimethoprim/sulfamethoxazole was significantly lower in PISP or in PRSP compared with PSSP (P , 0.0001) and PRSP compared with PISP (P 0.001).
SOAR: Russia 2014-16 JAC v17 blood (n " 4; 1.4%). Nine isolates (3.2%) were from an undisclosed respiratory source. Most isolates (n " 172; 61.6%) came from children, 91 (32.6%) were from adult patients (13-64 years) and 16 (5.7%) were from elderly patients. Forty-three isolates were b-lactamase positive (43/279; 15.4%) and 236 (84.6%) were b-lactamase negative. None was b-lactamase-negative-ampicillin-resistant (BLNAR) by CLSI breakpoints (ampicillin MIC 4 mg/L), but two were BLNAR by EUCAST breakpoints (ampicillin MIC 2 mg/L). Summary MIC and susceptibility data for all 279 H. influenzae isolates are shown in Table 4 . MIC distribution data are given in Table 5 .
All isolates were susceptible to ceftriaxone by all three breakpoint guidelines. Amoxicillin/clavulanic acid susceptibility was also 100% by CLSI and high-dose PK/PD breakpoints and 97.5% by EUCAST and low-dose PK/PD breakpoints. Levofloxacin and moxifloxacin susceptibility was 99.6% (278/279) for CLSI and PK/PD breakpoints, and slightly lower at 98.6% (275/279) with EUCAST breakpoints. Cefuroxime susceptibility was 98.2% (274/279) by CLSI, 76.0% (212/279) by PK/PD, but only 0.4% by EUCAST (1/279) breakpoints. Similarly, cefaclor susceptibility was considerably higher by CLSI (87.8%; 245/279) than by PK/PD (1.4%; 4/279) criteria; no EUCAST breakpoints are available. For azithromycin the same breakpoint guideline variability was observed, with high susceptibility using CLSI criteria (99.3%; 277/279), but greatly reduced susceptibility by PK/PD and EUCAST breakpoints (2.2%; 6/279). This breakpoint difference was also shown with clarithromycin susceptibility, although activity was much lower: 53.4% susceptible (149/279) by CLSI, 0% susceptible by PK/PD and 0.4% susceptible (1/279) by EUCAST. Trimethoprim/sulfamethoxazole susceptibility was 62.7% (175/279) by all three breakpoint categories.
Antibiotic susceptibility in H. influenzae was also compared according to specimen source and patient age group. There was no significant difference in antibiotic susceptibility based on patient age (data not shown). Percentage susceptibility data (CLSI breakpoints) by specimen source are shown in Figure 2 . For most antibacterials there was no significant difference in susceptibility by specimen source, but trimethoprim/sulfamethoxazole susceptibility was significantly lower for isolates from sinus specimens than those from bronchoalveolar lavage specimens (P " 0.001) or sputum samples (P " 0.005).
Discussion
Increasing antimicrobial resistance is a serious global problem that restricts empirical treatment options, which are essential for community-acquired respiratory tract infections. SOAR surveys antimicrobial resistance in key respiratory pathogens and is currently conducted throughout the Middle East, Africa, Latin America, Asia-Pacific and the Commonwealth of Independent States countries and has been running since 2002. It was established to provide information on local resistance patterns among the two most common pulmonary pathogens, S. pneumoniae and H. influenzae.
In this study, with lower oral dosing, 67.0% of pneumococci from Russia were found to be penicillin susceptible using CLSI oral breakpoints. Therefore, higher iv dosing is required to ensure positive clinical outcomes with penicillin. However, for many patients with community-acquired respiratory tract infections, oral therapy is desirable and fluoroquinolones (100% susceptible) and amoxicillin/clavulanic acid (95.0% susceptible) remain the optimum choices. However, fluoroquinolones are not recommended for the treatment of paediatric patients. Cefuroxime is also available orally but susceptibility was lower, at 85.0% (CLSI or PK/PD breakpoints) and 78.5% (EUCAST). Based on CLSI breakpoints, 68.8% of the pneumococci were susceptible to the macrolides azithromycin and clarithromycin, and although these agents can be given orally, they do not provide sufficient Torumkuney et al.
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coverage. Trimethoprim/sulfamethoxazole was also poorly active against pneumococci (68% susceptible). In addition, those isolates resistant to oral penicillin were also highly resistant to all other classes of antibiotic apart from fluoroquinolones, which further restricts therapeutic choices, especially for children, who cannot be given fluoroquinolones. H. influenzae from Russia were generally more susceptible to antimicrobial agents than S. pneumoniae, but nevertheless Percentage susceptibility rates (with 95% CI) for antimicrobials against H. influenzae by specimen source according to CLSI breakpoints. *Trimethoprim/sulfamethoxazole susceptibility was significantly lower in isolates from sinus specimens than in bronchoalveolar lavage (BAL) specimens (P " 0.001) or in sputum specimens (P " 0.005).
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